Truist Securities Boosts Jazz Pharmaceuticals Price Target to $230

Truist Securities raised its price target for Jazz Pharmaceuticals (JAZZ) to $230 from $220, a 4.55% increase. The firm maintains a "Buy" rating on the biopharmaceutical company. Analysts have provided a wide range of price targets, with an average of $216.60 and a high of $263.00. The average target implies an upside of 34.12% from the current price of $161.50.